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ABSTRACT
Approximately 170 million people worldwide are chronically infected by hepatitis C 
virus (HCV), which can result in progressive hepatic injury and fibrosis, culminating 
in cirrhosis and end-stage liver disease. The benchmark therapy for untreated HCV pa-
tients is a combination of pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). 
Several studies have suggested several potential new approaches to improve HCV ther-
apy—optimization of the dose and duration of RBV therapy, accompanied by careful 
clinical management, is crucial in ensuring the greatest likelihood of a long response 
to therapy. RBV causes serious side effects, but in clinical practice, there are no alterna-
tives for the treatment of HCV infection. Based on our results, weight-based doses of 
RBV are advantageous for genotype 1-infected patients, but its success in genotype 2- 
and 3-infected patients is unknown, particularly for shorter treatment durations.
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Background
Approximately  170  million  people  worldwide  are 
chronically infected by hepatitis C virus (HCV) (1), which 
can result in progressive hepatic injury and fibrosis, cul-
minating in cirrhosis and end-stage liver disease. Among 
adults in the Western world, chronic hepatitis C (CHC) is 
the major cause of cirrhosis and the principal indication 
for liver transplantation. CHC also contributes to the in-
creasing incidence of hepatocellular carcinoma (HCC), 
for which few satisfactory therapies exist (2). The primary 
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treatment goal in patients with chronic HCV infection is 
viral eradication. The benchmark therapy for untreated 
HCV-patients is a combination of pegylated interferon-
alpha  (PEG-IFN)  and  ribavirin  (RBV)  (3).  HCV  genotype 
should be systematically determined before treatment, 
because it dictates the indication, treatment duration, 
RBV dose, and virological monitoring procedure (4). HCV 
genotype 2- and 3-infected patients require 24 weeks of 
treatment and a low dose of RBV—i.e., 800 mg daily.
In contrast, HCV genotype 1-, 4-, 5-, and 6- infected pa-
tients require 48 weeks of treatment and a higher, body 
weight-based dose of RBV—i.e., 1000-1400 mg daily (4). 
This combination therapy is highly successful in patients 
infected with genotypes 2 and 3, effecting a sustained vi-
rologic response (SVR)—defined as undetectable serum Hepat Mon. 2011;11(4):240-246
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HCV RNA by quantitative PCR 24 weeks after the end of 
treatment—ranging between of 76% and 82% (5, 6). There 
is strong evidence that a treatment duration of 24 weeks 
yields equivalent SVR rates as 48 weeks (7). However, SVR 
rates in patients with genotype 1 infections, which con-
stitute approximately 70% of cases of CHC in the USA (8), 
are lower, wherein 42% to 46% of patients achieve SVR af-
ter 48 weeks of combination therapy. Several new, potent 
HCV protease and polymerase inhibitors have been de-
scribed recently (9), but none is available in clinical prac-
tice. Higher response rates are observed in the majority 
of patients who are able to tolerate and adhere to RBV, 
suggesting that cumulative RBV exposure is important. 
Optimization of RBV dose and duration of therapy, in 
conjunction with careful clinical management, is crucial 
in ensuring the greatest chance for a durable response to 
the therapy.
This report will review the clinical role of RBV and, in 
particular, the selection and maintenance of the optimal 
RBV  dosing  strategy  that  are  required  to  achieve  sus-
tained viral suppression in patients with chronic HCV 
infection.
Current treatment schedule
Combination therapy with PEG-IFN and RBV has been 
reported in large clinical trials to effect high SVR rates 
and, correspondingly, low rates of virologic relapse (10). 
However,  the  response  rate  to  antiviral  therapy  varies 
according to HCV genotype. HCV genotypes 2 and 3 are 
more  responsive  to  therapy  than  genotype  1,  having 
comparatively higher SVR rates with most therapeutic 
options (11, 12). Despite the good response of genotype 2 
and 3 patients to therapy, there is still a clear benefit of 
adding RBV to therapy with PEG-IFN, and SVR rates of ap-
proximately 80% have been reported with this combina-
tion (13). The impact of PEG-IFN and RBV on the response 
of other HCV genotypes (4-6) has not been as well exam-
ined, because these genotypes are rarer and tend to be 
pooled in analyses or excluded altogether from larger 
trials. Although patients with genotype 1 infection are 
generally less responsive to therapy, an SVR to combi-
nation  therapy  is  still  observed  in  approximately  50% 
of such patients (5, 14). A large, randomized, controlled 
study, comparing PEG-IFN alpha-2a alone (180 μg/week) 
with PEG-IFN alpha-2a plus RBV (1000/1200 mg/day) or 
interferon alpha-2b (3 MU thrice weekly) plus RBV over 
48 weeks clearly demonstrated that RBV significantly im-
proves outcomes in genotype 1-infected patients (6).
Ribavirin in the treatment of HCV chronic 
infection
RBV  monotherapy  is  not  efficacious  against  chronic 
HCV  infection.  Some  placebo-controlled  clinical  trials 
have shown that RBV reduces serum transaminase lev-
els and HCV RNA concentrations, but both parameters 
returned to pre-treatment levels after the therapy was 
halted  (15,  16).  Moreover,  RBV  alone  had  no  effects  on 
liver histology. When it is combined with standard or 
PEG-IFN, RBV enhances the virological, biochemical, and 
histological response compared with IFN alone (12, 17). 
Further development of this therapeutic model, taking 
into account the anti-HCV activity of RBV, has fit well with 
the experimental data, showing that the addition of RBV 
enhances SVR rates by approximately 25% to 30% and sug-
gesting a mechanism by which RBV enhances declines in 
HCV RNA and improves long-term outcome (18).
Reductions  in  RBV  dose  negatively  affect  SVRs  in  pa-
tients who are infected with HCV genotype 1, and higher 
RBV doses are associated with higher SVR rates in patients 
who are treated with PEG-IFN alpha-2b plus RBV (19). In 
addition,  genotype  1-infected  patients  who  were  ran-
domized to PEG-IFN alpha-2a plus 1000/1200 mg/day RBV 
had higher SVR rates than those given PEG-IFN alpha-2a 
plus 800 mg/day RBV, further indicating the significance 
of adequate RBV dosing (5). Both the timing of dose re-
duction and lower relative doses affect SVR. For example, 
a retrospective analysis showed that reductions in RBV 
dose during the first 12 weeks of treatment affected the 
early virologic response (EVR), defined as undetectable 
HCV RNA < 50 IU/mL by qualitative PCR or a ≥ 2-log de-
crease in HCV RNA at Week 12 in patients infected with 
HCV genotype 1 (20).
Assessment of ribavirin dose
A physician who prescribes RBV must select the appro-
priate starting dose, maintaining it by careful clinical 
management of any RBV-related side effects and incre-
mentally decreasing the dose, and he must determine 
when the patient should return to the indicated dose 
following  successful  management  of  side  effects.  It  is 
also crucial to continue RBV to the end of therapy if pos-
sible, because late discontinuation can adversely affect 
clinical outcomes. RBV monotherapy does not induce a 
significant antiviral response in patients with chronic 
HCV infection, but in combination with IFN, it markedly 
improves the rate of end of treatment response (ETR)—
defined as undetectable serum HCV RNA at the end of 
the treatment—reduces relapse rate,s and increases SVR 
rates. Since the synthesis of RBV in the early 1970s, sever-
al mechanisms of action have been proposed and might 
vary between viruses. For the treatment of chronic HCV 
infection, the following mechanisms are currently con-
sidered:  (i)  immunomodulatory  properties,  (ii)  inhibi-
tion  of  inosine  monophosphate  dehydrogenase  (IMP-
DH), (iii) direct inhibition of the HCV-encoded NS5B RNA 
polymerase, (iv) induction of lethal mutagenesis, and (v) 
modulation of interferon-stimulated gene (ISG) expres-
sion (21, 22) (Figure 1). 
A relationship between RBV dose and response to ther-
apy with both IFN alpha-2a and alpha-2b has been estab-
lished in genotype 1 patients, who benefit from doses 
that exceed 800 mg/day (5, 14). When RBV is combined 
with PEG-IFN alpha-2a, relatively small reductions to 800 Hepat Mon. 2011;11(4):240-246
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mg/day lead to significantly lower rates of SVR (5). Simi-
larly,  a  large  comparative  trial  of  fixed-dose  RBV  com-
pared  with  weight-based  dosing  in  combination  with 
PEG-IFN alpha-2b demonstrated that stratifying patients 
of all genotypes to receive starting doses ranging from 
800-1400  mg/day  depending  on  weight  effects  higher 
SVR rates than using a fixed dose of 800 mg/day for all pa-
tients (7). A detailed analysis of the relationship between 
body weight and SVR has suggested that the dose per 
kilogram is the determining factor of response in geno-
type 1 patients, based on the 40% to 50% rise in SVR for a 
12-16-mg/kg increase in RBV dose (23). RBV dose by weight 
may impact its concentration in plasma, which also cor-
relates with the response. Although this relationship has 
been well documented in genotype 1 patients, the data 
are less clear for other genotypes. A relationship between 
response and plasma concentration has been proposed 
for non-genotype 1 patients (24). However Snoeck et al. 
observed no effect of dose per kilogram body weight on 
SVR in genotype 2/3 patients (23).
Based  on  these  data,  weight-based  dosing  has  been 
used more extensively in patients with genotype 1 HCV, 
and it is required to achieve maximum efficacy. The stan-
dard initial dose of RBV in patients with HCV genotype 1 
is 1000/1200 mg/day (1000 mg/day ≤ 75 kg; 1200 mg/day 
> 75 kg) over a 48 weeks, although higher RBV doses are 
considered for patients > 85 kg. A study of 380 patients 
has shown that the pharmacokinetics of RBV vary widely, 
wherein lean body weight emerges as the only factor that 
inﬂuences  clearance,  supporting  the  use  of  these  two 
distinct weight-based doses in patients with genotype 1 
disease (25). Although data modeling from patients who 
received this standard starting dose suggests that SVR in-
creases linearly with RBV doses that equate to > 10 mg/
kg, the rate of anemia also rises linearly simultaneously 
(< 10 g/dL hemoglobin) (23). An RBV dose of 15 mg/kg/day 
might achieve the best balance between efficacy and a 
manageable safety profile.
The impact of dose reduction on SVR was assessed ret-
rospectively  by  analyzing  drug  exposure  in  genotype 
1-infected  patients  who  were  randomized  to  PEG-IFN 
alpha-2a (180 μg/week) plus RBV (1000 or 1200 mg/day) 
and completed 48 weeks of treatment (4). Neither EVR 
nor  SVR  was  adversely  affected  by  reductions  in  RBV 
dose, as long as the cumulative ribavirin exposure was 
greater than 60% of the intended dose, whereas the SVR 
rate in patients who received a lower dosage of RBV was 
significantly lower (33% vs. 64%; p < 0.0001). Notably, RBV 
dose reductions during weeks 5-48 had minimal impact 
on SVR in patients who achieved rapid virologic response 
(RVR), defined as undetectable serum HCV RNA levels at 
4 weeks, even when the cumulative RBV dose was less 
than 60% of the intended dose. In patients who did not 
achieve RVR, however, reductions in RBV dose after Week 
4 had a negative impact on SVR rate in all RBV exposure 
categories.
When non-responders to IFN, with or without RBV, were 
re-treated with PEG-IFN alpha-2a plus RBV, RBV dose re-
ductions during Weeks 1-20 were associated with reduced 
a SVR rate (21% to 11%; p = 0.031), whereas later RBV dose 
reductions did not affect SVR rates. In addition, patients 
who were initially treated with IFN mono-therapy had a 
higher probability of attaining a SVR during retreatment 
with PEG-IFN alpha-2a plus RBV than those who were ini-
tially treated with interferon and RBV. Further analysis 
in re-treated patients has shown that reductions in RBV 
dose during the first 12 or 20 weeks of treatment do not 
significantly affect SVR rates as long as patients remain 
on full-dose PEG-IFN alpha-2a. However, discontinuation 
of RBV during the first 20 weeks of therapy or drug in-
terruption for at least 7 consecutive days during the first 
12 weeks had a negative impact on SVR. In addition, RBV 
dose reductions during the following 20-40 weeks did 
not have a consistent effect on SVR, as long as PEG-IFN 
alpha-2a dose was maintained and RBV was not discon-
tinued (26).
To assess the role of RBV in HCV clearance and evaluate 
the consequences of RBV discontinuation, 516 patients 
who  were  infected  with  HCV  genotype  1  were  treated 
with 180 μg/week of PEG-IFN alpha-2a and 800 mg/day of 
RBV. Those subjects who were HCV RNA-negative at Week 
24 were randomized to further treatment with PEG-IFN 
alpha-2a  plus  RBV  or  PEG-IFN  alpha-2a  alone  (27).  Re-
sponders at Week 24 who stopped RBV had higher rates 
of  breakthrough  during  treatment  and  relapse  after 
therapy than those who continued on both agents (SVR 
rates, 52.8% vs 68.2%; p = 0.004). However, the side effect 
profile and quality of life of patients who discontinued 
RBV tended to improve. Recently, Ferenci et al. have been 
investigated efficacy and tolerability of 24 weeks of treat-
ment with RBV 800 mg/day or 400 mg/day plus PEG-IFN 
alpha-2a 180 μg/week in 141 treatment-naïve patients who 
were infected HCV genotype 2 or 3. Data suggests that 
400 mg/day of RBV enough in patients infected with HCV 
genotype 3 to achieve as high SVR rates as those attained 
by the standard 800 mg/day dosing (SVR: 63.9% versus 
67.5%), whereas the same results could not be replicated 
in patients with HCV genotype 2. In the latter patients 
the SVR rates following low-dose RBV were significantly 
lower than those attained with a standard dose of RBV 
(55.6% versus 77.8%) (28).
Recent studies suggest that high-dose RBV in combina-
tion with PEG-IFN can improve responses in genotype 
1-infected patients. Lindahl et al. used an individualized 
dosing regimen, based largely on renal function, in an at-
tempt to achieve a steady-state RBV concentration great-
er than 15 μmol/l in 10 treatment-naïve patients (29). After 
initial dose adjustments, the mean dose of RBV was 2,540 
mg per day (range 1,600-3,600 mg), and the mean RBV 
concentration was 14.7 μM (range 7.8-22.0 μM) at Weeks 
24-48. Nine of 10 patients achieved an SVR, but the side ef-
fects, in particular anemia that required erythropoietin, 
were much more frequent and severe. The impact of dose 
reduction on SVR was assessed retrospectively by analyz-Hepat Mon. 2011;11(4):240-246
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ing drug exposure in genotype 1-infected patients who 
were  randomized  to  PEG-IFN  alpha-2a  (180  mg/week) 
plus RBV (1000 or 1200 mg/day) who completed 48 weeks 
of treatment (30). Neither the EVR or SVR was adversely 
affected by RBV dose reduction as long as cumulative RBV 
exposure was > 60%, whereas the SVR rate in patients re-
ceiving > 60% RBV was significantly lower than in those 
receiving > 60% RBV (33% vs 64%; p < 0.0001). Patients 
who received ≤ 60% RBV dosing experienced prolonged 
periods  of  dose  reduction,  interruption  of  therapy,  or 
premature discontinuation. Even in patients with a > 97% 
cumulative RBV dose over Weeks 1-12, the SVR rate was sig-
nificantly lower in those with ≤ 80% RBV exposure than 
in those with > 80% exposure during Weeks 13-48 (48% vs 
67%; p = 0.372). In contrast, RBV dose reductions during 
Weeks 5-48 had a minimal impact on SVR in patients who 
achieved RVR, even when the cumulative RBV dose was < 
60%. In patients who did not achieve RVR, however, RBV 
dose reductions after Week 4 had a negative impact on 
SVR rate in all RBV exposure categories.
More recently, in a prospective, open-label, randomized, 
controlled pilot study comparing 48 weeks of treatment 
with  PEG-IFN  plus  standard  weight-based  RBV  with  or 
without erythropoietin (groups 1 and 2) and PEG-IFN plus 
higher weight-based RBV plus erythropoietin (group 3), 
SVR was significantly greater in group 3 patients due to a 
significant decline in relapse rate (31).
 Ribavirin dosage and adverse events
The main serious adverse event that is associated with 
the use of RBV is dose-dependent hemolytic anemia. Ane-
mia is frequently observed in patients receiving combina-
tion treatment with standard interferon or PEG-IFN plus 
RBV (5, 12). RBV-induced anemia has been shown to be 
primarily affected by plasma RBV concentration, not by 
dose per kilogram body weight (32). A recent publication 
supports the individualization of RBV dosing according 
to HCV genotype and body weight and highlights several 
clinical variables that have an effect on the likelihood of 
SVR versus the occurrence of anemia (23). A higher appar-
ent clearance of RBV, older age, and cirrhosis have a nega-
tive impact on achieving an SVR. Gender and RBV dose/
kg  are  the  most  important  prognostic  factors  for  the 
occurrence of anemia. However, because anemia is not 
a universal risk in all treated patients, the initial high-
dose strategy of 1,000 or 1,200 mg per day based on body 
weight, appears to be appropriate. For heavier patients, 
RBV doses greater than 1,200 mg/day may be initiated, 
because they are likely to be associated with additional 
efficacy and a manageable risk of anemia (23).
Few studies have shown that erythropoietin can be used 
to improve quality of life, maintain RBV dose, and subse-
quently improve adherence to therapy (33, 34). Although 
erythropoietin may have a role in the management of 
RBV-related anemia, a recent study failed to show an im-
provement of SVR in genotype 1-infected patients who 
were given epoetin alpha at the initiation of therapy to 
Figure 1. Proposed mechanisms of action of ribavirin. IMPDH, inosine monophosphate dehydrogenase; TH, T helper cell. TNF, tumor necrosis factor.
(Reprinted with permission from J.J. Feld and J.H. Hoofnagle. Mechanism of action of interferon and ribavirin in treatment of hepatitis C Jordan J. Nature 
2005, 436:967-972.)Hepat Mon. 2011;11(4):240-246
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maintain hemoglobin levels between 12 and 15 g/dL (35). 
This was a three-arm, prospective, open-label, random-
ized, controlled pilot study comparing 48 weeks of treat-
ment with PEG-IFN plus standard weight-based RBV with 
or without erythropoietin (groups 1 and 2) and PEG-IFN 
plus higher weight-based RBV plus erythropoietin (group 
3). A significantly smaller percentage of group 2 patients 
experienced a decline in hemoglobin to less than 10 g/dL 
(9% vs 34%; p < 0.05) and required a more frequent dose 
reduction of RBV compared with group 1 patients (10% vs 
40%; p < 0.05). Nevertheless, SVRs were similar in the two 
latter groups (19% vs. 29%). SVR was significantly higher 
in group 3 patients (49%) due to a relevant decline in re-
lapse rate.
It has been suggested that the use of erythropoietin 
may be an appropriate strategy for managing anemia, 
improving quality of life, and increasing adherence to 
therapy, particularly in patients with genotype 1 infection 
(29). However, its use has not been permitted in registra-
tion trials of PEG-IFNs and RBV, and no recommendation 
for its use in RBV-associated anemia has been included 
in EU and USA labels (36, 37). The limited data available 
concerning the use of erythropoietin are insufficient to 
make  clear  recommendations.  If  shortening  the  treat-
ment below the standard duration is to be considered, 
careful reassessment of RBV dose is necessary, because 
RBV dose and treatment duration appear to be closely 
linked. In a prospective study, reducing the dose of RBV 
to 400 mg did not adversely affect the rate of SVR com-
pared with the standard 800 mg daily dose in genotype 
2- and 3-infected patients who were treated for 24 weeks 
(28).
Another adverse event that is associated with RBV is 
loss of bone mineral density (BMD). When parameters of 
BMD were assessed in 13 patients who were treated with 
interferon alone and 19 who were treated with interferon 
plus RBV, the latter had significantly lower BMD (1.108 ± 
0.08 g/cm2 vs. 0.877 ± 0.07 g/cm2; p < 0.001), T-scores (0.19 
± 0.6 vs -1.94 ± 0.6; p < 0.001), and Z-scores (0.26 ± 0.6 vs. 
-1.7 6 ± 0.5; p < 0.001) by magnetic resonance imaging; 
urinary calcium excretion (218 ± 97 mg/24 h vs. 76 ± 36 
mg/24h; p < 0.001); and calcium/creatinine ratios (1.9 ± 
0.3 mg/mg vs. 0.06 ± 0.02 mg/mg; p < 0.01) (38). Other 
studies reported no loss in BMD in a group of 12 patients 
with recurrent HCV infection after orthotopic liver trans-
plantation (39).
Pre- and post-treatment measurements showed no dif-
ferences in BMD between 13 pediatric patients who were 
treated with PEG-IFN alpha-2b and RBV and 7 patients 
who were treated with interferon alone (40). Although 
incubation  of  human  osteoclast-like  cells  with  inter-
feron for up to 14 days had no effect on cell growth, RBV 
significantly  reduced  cell  proliferation,  increased  cell 
death, and reduced alkaline phosphatase (ALP) activity, 
indicating that it suppresses osteoblast differentiation 
(41, 42). In contrast, RBV had little effect on the prolifera-
tion or ALP activity of murine osteoblasts and no direct 
effect on osteoclast differentiation or function, although 
it indirectly induced TRANCE/RANKL gene expression in 
osteoblasts,  thus  enhancing  osteoclast  formation  (43). 
These findings suggest that the involvement of RBV in re-
ducing BMD is unclear, necessitating further study.
Lower doses of RBV may also be appropriate in certain 
patient groups who can not otherwise tolerate RBV ther-
apy, such as those with renal impairments. With careful 
monitoring of plasma concentrations to avoid overdos-
ing, RBV doses of 200-800 mg/day have been successfully 
administered in a small cohort of renally impaired pa-
tients (19). The literature suggests that 200-400 mg/day of 
RBV can be given safely and may allow for more success-
ful treatment (30). Recurrence of HCV chronic infection 
is universal in patients who require liver transplantation 
for this indication, but many transplant recipients have 
some degree of renal impairment. In a group of trans-
plant patients who were treated with interferon and RBV, 
the incidence of hemolysis was related to the degree of 
renal impairment, suggesting that the RBV dose should 
be adjusted to reduce hemolysis (44). In addition, phar-
macokinetic studies in HCV-positive kidney or liver trans-
plant patients have shown that RBV dosage is dependent 
on renal function and that monitoring plasma ribavirin 
concentrations during treatment can maximize efficacy 
while reducing side effects (45).
Discussion
The milestone in contemporary therapy of chronic HCV 
infection is to deliver doses of both agents that confer op-
timal antiviral efficacy for a sufficient time to minimize 
viral relapse. At the same time, it is important to mini-
mize the impact of side effects that might erode the ef-
fectiveness of therapy due to dose reductions below the 
level of therapeutic efficacy or because the patient is un-
able to complete an optimal treatment course. The asso-
ciation between RBV and PEG-IFN improves SVR rates and 
decreases the rate of relapse in patients with HCV infec-
tion. Thus, combined treatment is considered the bench-
mark therapy. A number of mechanisms, including di-
rect inhibition of RNA replication, immunomodulation, 
inhibition  of  inosine  monophosphate  dehydrogenase, 
and enhanced viral mutagenesis, have been proposed to 
explain the role of RBV.
However, many questions remain open (28, 46). Clinical 
evidence has shown the importance of RBV in the treat-
ment of hepatitic C infection, and research suggests a 
number of potential approaches to optimizing HCV ther-
apy to increase SVR rates. However, this drug is associated 
with frequent side effects, necessitating dose reductions 
and/or discontinuation. For this reason, patient manage-
ment is required to monitor the toxicities of therapy; in 
particular,  hemoglobin  levels  should  be  monitored  in 
patients with risk factors for treatment-induced hemo-
lytic anemia, and dose reductions or other therapeutic 
interventions should be administered in a timely man-
ner (47). Dose reductions in RBV should be limited to the Hepat Mon. 2011;11(4):240-246
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minimum that is required to address side effects, possi-
bly using small decrements and avoiding reductions to 
below 60% of the target dose whenever possible.
At present, there are no alternatives to RBV for the treat-
ment of HCV infection, and therefore, maintaining pa-
tients on their indicated dose and length of therapy is 
crucial if the goal of a high rate of SVR is to be achieved. 
However, due to the limited data available, further stud-
ies on RBV dose and treatment duration are warranted 
before any recommendations can be made. In our opin-
ion, weight-based dosing of RBV is advantageous for gen-
otype 1-infected patients, while its relevance for genotype 
2- and 3-infected patients remains to be further clarified, 
particularly for shorter treatment durations.
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